Abstract
BackgroundThe association between a 4‐bp indel polymorphism (rs10680577) within the distal promoter of EGLN2 and cancer risk has been investigated by several case–control studies in recent years, but investigation results were inconsistent. Thus, a systematic assessment of the association was performed based on a literature review and pooled analysis.MethodsTwo investigators independently retrieved relevant studies from PubMed, Chinese National Knowledge Infrastructure (CNKI), Embase, and Google Scholar. The fixed or random effects model was selected to calculate odds ratios (ORs) with 95% confidence intervals (CIs) based on heterogeneity level. All analyses including heterogeneity assessment, subgroup analysis, sensitivity analysis, and publication bias assessment were performed using RevMan 5.3 software and Stata 12.0 software.ResultsA total of six relevant studies with 3,406 cases and 5,147 controls were included in the final analysis. The overall pooled analysis showed that EGLN2 rs10680577 polymorphism was significantly associated with cancer risk under all genetic models. However, subgroup analysis based on cancer type showed that the polymorphism was significantly associated with the risk of digestive system cancer under all genetic models, and with the risk of lung cancer under dominant model, heterozygote comparison model, and allele comparison model. Subgroup analysis based on population sources showed a significant association in Chinese population under all genetic models.ConclusionThe present result suggests that EGLN2 rs10680577 polymorphism is associated with cancer risk, and may act as a promising predictive biomarker for cancer risk, especially in Chinese population. However, further well‐designed studies are warranted to confirm these results.
Highlights
Cancer is one of the most common disorders causing considerable mortality
In the year 2012, Zhu et al firstly investigated the association between a 4‐bp indel polymorphism within the distal promoter of EGLN2 and cancer risk based on two independent case–control studies, and found that the deletion allele of rs10680577 polymorphism was significantly associated with increased risk of hepatocellular carcinoma
More studies including a meta‐analysis were conducted to explore the association of the rs10680577 polymorphism with the risk of cancer, including lung cancer, gastric cancer, colorectal cancer, and breast cancer (Che et al, 2014; Hashemi, Danesh, et al, 2018; Hashemi, Tabasi, & Ansari, 2018; Li et al, 2017; Wang et al, 2014; Zhu et al, 2019)
Summary
Cancer is one of the most common disorders causing considerable mortality. Its etiology is complex and involved in environmental and genetic factors. Several studies have focused on the association between a functional polymorphism within EGLN2 and the risk of cancers, including breast cancer, lung cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma (Che et al, 2014; Hashemi, Danesh, et al, 2018; Li et al, 2017; Wang, Zhang, Zhou, Chen, & Yu, 2014; Zhu, Luo, & Li, 2019; Zhu et al, 2012). This functional polymorphism is a 4‐bp insertion/deletion (indel) polymorphism (rs10680577) within the distal promoter of EGLN2, which can affect the expression of EGLN2 (Zhu et al, 2012). In view of the fact that meta‐analysis is a statistical analysis that has the capacity to contrast results from different studies and identifies sources of disagreement among those results, or other interesting relationships that may come to light in the context of multiple studies, we utilized the method to systematically assess the association of the rs10680577 polymorphism with cancer risk in the present study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
